Has Daniel Schneider received payments from drug or device companies?

Yes. Drug and device makers reported $137,146 in general payments to Daniel Schneider across 142 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Daniel Schneider did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Daniel Schneider come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Daniel Schneider

Neurology · New Brunswick, NJNPI 1891840781

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $122,632 of the $137,146 with a category attached, or 89.4%. 10 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 51.1% of the total. Reporting peaked in 2019 at $112,499 and has fallen 99.6% since, to $443 in 2024. Among neurology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$137,146in general payments, 2019–2025

Across 142 payments — averaging $965.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Teva Pharmaceuticals USA, Inc.$70K
Neurocrine Biosciences, Inc.$57K
Acadia Pharmaceuticals Inc$9K
Biogen$565
Abbott$326
Johnson & Johnson$299
plus $537 from 4 others

$19,084in research payments, 2019–2025

Across 9 payments — averaging $2120.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Acadia Pharmaceuticals Inc$18K
Medtronic$725

What the payments were for

Consulting fees$3,1002%
Speaking & faculty fees$122,63289%
Travel & lodging$8,0196%
Food & beverage$3,3952%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Teva Pharmaceuticals USA, Inc.	45	$70,150
Neurocrine Biosciences, Inc.	65	$56,663
Acadia Pharmaceuticals Inc	7	$8,606
Biogen	1	$565
Abbott	4	$326
Johnson & Johnson(2 entities)	14	$299
Phenox Inc.	1	$180
Boston Scientific	3	$161
Medical Device Business Services, Inc.	1	$144
Medtronic	1	$53

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$137,146 in reported general payments places this provider in the 95th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey →

Other neurology in New Brunswick

Suhayl Dhib-JalbutNew Brunswick$64K
Steven BromleyAudubon$1.5M
Mary Ann PiconeTeaneck$1.5M
Fiona GuptaOradell$1.1M
Matthew DavisMiddletown$567K
Amos KatzEatontown$558K
Monte PellmarFreehold$429K
Marcie RabinSummit$387K
Ashish KapoorBayonne$329K
Mario VukicHackensack$310K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →